Not Signed In -
Travoprost |
Travatan |
Clinical Trial: A safety and efficacy study of Travoprost 0.004% compared to Latanoprost 0.005% in patients with chronic angle-closure glaucoma
This study is currently recruiting patients.
|
Purpose
To demonstrate that the intraocular pressure(IOP)-lowering efficacy of Travoprost (0.004%) is equal or better than that of Latanoprost 0.005% in patients with chronic angle-closure glaucoma.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Glaucoma, Angle-Closure Ocular Hypertension | Drug: Travoprost (0.004%) Drug: Latanoprost (0.005%) | Phase III |
MedlinePlus related topics: Eye Diseases; Glaucoma
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title: A safety and efficacy study of Travoprost 0.004% compared to Latanoprost 0.005% in patients with chronic angle-closure glaucoma.
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both
Criteria
Adult patients of any race and either sex with chronic angle-closure glaucoma.
Location and Contact Information
Alcon Clinical +1-817-568-6747 IntlDev@alconlabs.com
Australia, ; Recruiting
Asia, ; Recruiting
More Information
Study ID Numbers: C-01-38
Record last reviewed: January 2003
Last Updated: January 7, 2003
Record first received: January 3, 2003
ClinicalTrials.gov Identifier: NCT00051181
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Record last reviewed: January 2003
Last Updated: January 7, 2003
Record first received: January 3, 2003
ClinicalTrials.gov Identifier: NCT00051181
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005
Resources
- Travatan (Drug Digest)
- Travatan Consumer Information (U.S. Food and Drug Administration)
email this page
print this page
bookmark this page
feedback on this page
